What “Fidaxomicin 200 mg LOE” usually refers to
“LOE” commonly means “loss of exclusivity,” a date after which a manufacturer may face reduced protection against generic or competing products. In the case of fidaxomicin 200 mg, LOE would typically be tied to patent and related exclusivity protections that block or delay generic entry.
When would LOE for fidaxomicin 200 mg happen?
The exact LOE date depends on the specific protection being referenced (for example, drug product patents, method patents, or regulatory exclusivities) and on the country/market. Without the country, brand name (the best-known fidaxomicin brand is Dificid), and the specific database/source you mean by “LOE,” there is no single verifiable date I can state.
Which patents usually drive LOE for fidaxomicin?
LOE timing for brand drugs like fidaxomicin is often driven by:
- Patent expiry (including any “patent term adjustments” or extensions)
- Regulatory exclusivities (where applicable)
- Market-specific factors such as pediatric exclusivity or other statutory protections
If you share the missing details, I can pin down the LOE date
Reply with any one of the following and I’ll narrow it to the correct LOE:
- The country/market (US, EU, UK, etc.)
- The brand name you’re tracking (e.g., Dificid)
- The source you’re using for “loe” (for example, specific payer/market access tool output)
- The patent number(s) you’re referring to (if you have them)
Can generics enter before LOE?
Even after a patent “loss of exclusivity” date is reached, actual generic launch timing can still be influenced by:
- Remaining patents covering new uses or formulations
- Litigation outcomes (if a generic challenges a patent)
- Regulatory approval timelines and launch strategy
If you tell me the market (e.g., US) and what “LOE” source you’re using, I can explain how generics typically line up relative to that date.
---
Sources
No sources were provided with your question, so I cannot cite or verify an LOE date.